Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein
- PMID: 33846219
- PMCID: PMC8054958
- DOI: 10.1212/NXI.0000000000000965
Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein
Abstract
Objectives: Information on subclinical astrocyte damage can provide further insight into neuromyelitis optica spectrum disorder (NMOSD) pathophysiology and disease-monitoring strategies. To investigate whether astrocyte and neuroaxonal damage occurs during interattack periods in individuals with NMOSD through longitudinal measurement of serum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) at multiple time points.
Methods: sGFAP and sNfL levels were measured in 187 serum samples from 20 participants with NMOSD treated with rituximab (median follow-up: 24 months) and 19 age-/sex-matched healthy controls using a highly sensitive single-molecule array assay. From the NMOSD cohort of National Cancer Center, Korea, 14 clinically stable participants were randomly selected for focused investigation of interattack periods, and 6 participants with clinical attacks despite treatment were enrolled for attack-related measurements.
Results: Significant elevations of sGFAP levels were observed in all clinical attacks, and 95% (19/20) of patients showed reduction of sGFAP levels below the cutoff value (3 SDs above mean levels in age-/sex-matched healthy controls) within 3 months of their clinical attacks. The sGFAP levels were consistently low during interattack periods in 90% (17/19) of patients whose sGFAP levels returned to below the cutoff value. Changes in sNfL levels were similar to but slower than those in sGFAP levels.
Conclusions: Subclinical astrocyte damage represented by increasing sGFAP levels rarely occurred during interattack periods in individuals with NMOSD; however, a certain degree of astrocyte damage did occur at the time of clinical attacks without exception, but it was not evident within 3 months of the attack.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
Comment in
-
The Calm Between Storms: Serum Biomarkers in Assessing Interattack Astrocytopathy in Neuromyelitis Optica Spectrum Disorder.Neurol Neuroimmunol Neuroinflamm. 2021 Apr 9;8(3):e988. doi: 10.1212/NXI.0000000000000988. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33846269 Free PMC article. No abstract available.
Similar articles
-
Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.J Neurochem. 2021 Dec;159(5):913-922. doi: 10.1111/jnc.15478. Epub 2021 Jul 28. J Neurochem. 2021. PMID: 34278578
-
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.J Neuroinflammation. 2021 May 1;18(1):105. doi: 10.1186/s12974-021-02138-7. J Neuroinflammation. 2021. PMID: 33933106 Free PMC article.
-
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.JAMA Neurol. 2025 Feb 1;82(2):168-175. doi: 10.1001/jamaneurol.2024.4400. JAMA Neurol. 2025. PMID: 39714824
-
Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein.Neurol Sci. 2024 Mar;45(3):1255-1261. doi: 10.1007/s10072-023-07277-8. Epub 2023 Dec 23. Neurol Sci. 2024. PMID: 38141119 Review.
-
Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.Expert Rev Clin Immunol. 2023 Jan;19(1):71-91. doi: 10.1080/1744666X.2023.2148657. Epub 2022 Nov 30. Expert Rev Clin Immunol. 2023. PMID: 36378751 Review.
Cited by
-
Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders.Front Neurol. 2022 Mar 17;13:865730. doi: 10.3389/fneur.2022.865730. eCollection 2022. Front Neurol. 2022. PMID: 35370870 Free PMC article. Review.
-
Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder.Ther Adv Neurol Disord. 2021 Nov 3;14:17562864211054952. doi: 10.1177/17562864211054952. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34777577 Free PMC article.
-
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.J Neurol. 2025 Apr 14;272(5):339. doi: 10.1007/s00415-025-13064-6. J Neurol. 2025. PMID: 40227344 Free PMC article.
-
Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.J Neurol. 2023 Jul;270(7):3341-3368. doi: 10.1007/s00415-023-11634-0. Epub 2023 Apr 6. J Neurol. 2023. PMID: 37022481 Free PMC article. Review.
-
Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.Neurol Ther. 2024 Jun;13(3):535-549. doi: 10.1007/s40120-024-00597-7. Epub 2024 May 9. Neurol Ther. 2024. PMID: 38722571 Free PMC article. Review.
References
-
- Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575–577. - PubMed
-
- Watanabe M, Nakamura Y, Michalak Z, et al. . Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 2019;93:e1–e13. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources